Latest Breaking News On - Mycotic infections - Page 1 : comparemela.com

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date .

United kingdomUnited statesNational institute of diabetesInternational diabetes federationDrug administrationUs centers for diseaseNational diabetes statisticsEuropean medicines agencyCenters for diseaseExecutive vice presidentBiopharmaceuticals business unitDisease controlNew england journalMedicine evidenceMycotic infectionsCommon adverse reactions

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesUs centers for diseaseNational diabetes statisticsProduct serviceInternational diabetes federationNational institute of diabetesDrug administrationCenters for diseaseEuropean medicines agencyExecutive vice presidentBiopharmaceuticals business unitDisease controlNew england journalMycotic infectionsCommon adverse reactions

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo - Lexicon Pharmaceuticals (NASDAQ:LXRX)

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport

Ann arborUnited statesNew yorkLivia stangerLisa defrancescoCraig granowitzAlina cocuzzaMario enrico canonicoPreston masonRahul aggarwalUniversity of coloradoIcahn school of medicine at mount sinaiDrug administrationClinical researchUniversity of michiganAmerican college of cardiology

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of.

United statesSan diegoLisa defrancescoMichaelj daviesCraig granowitzAlina cocuzzaDiabetic neuropathy study group neurodiabLexicon pharmaceuticals incDevelopment rd expensesAmerican heart association scientific sessionsCompany toHeart failure society of americaGlobenewswire incEuropean association for the study of diabetesLexicon pharmaceuticalsExchange commission

2023-11-12 | NDAQ:LXRX | Press Release | Lexicon Pharmaceuticals Inc

(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

United statesAlina cocuzzaRahul aggarwalFournier closecurlyquoteCraig granowitzScience session of the american heart associationLexicon pharmaceuticals incDrug administrationLexicon pharmaceuticalsAmerican heart associationExchange commissionScientific sessionsWomen closecurlyquoteLexicon closecurlyquoteConcomitant useInsulin secretagogues